Published in Biochem Pharmacol on May 12, 2017
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res (2003) 13.22
Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res (2006) 8.26
SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem (1989) 5.64
Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem (1995) 5.57
Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem (1993) 4.90
Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest (1999) 3.28
Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem (1990) 3.25
Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol (2007) 3.19
Preeclampsia: recent insights. Hypertension (2005) 2.98
Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int (2007) 2.87
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem (1998) 2.71
Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension (2007) 2.53
Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J (2001) 2.23
Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension (2005) 2.22
Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab (2003) 2.07
Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension (2001) 2.04
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol (2005) 2.03
Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. Hypertension (2005) 1.95
Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Manag (2011) 1.86
Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade. Hypertension (2008) 1.78
Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation (2002) 1.78
Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension (2008) 1.72
EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal (2009) 1.66
Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem (1998) 1.65
Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr Hypertens Rep (2007) 1.65
Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am J Respir Cell Mol Biol (1997) 1.53
A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett (1992) 1.51
Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension (2008) 1.45
Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J Biol Chem (2000) 1.43
Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem (1995) 1.42
Decreased endothelium-dependent vascular relaxation during reduction of uterine perfusion pressure in pregnant rat. Hypertension (2000) 1.37
Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP). FEBS Lett (1996) 1.37
Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models. Am J Physiol Regul Integr Comp Physiol (2002) 1.36
Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question. Endocrinology (2004) 1.33
CD4+ T-helper cells stimulated in response to placental ischemia mediate hypertension during pregnancy. Hypertension (2011) 1.32
Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J Biol Chem (2010) 1.31
Physiologic changes during normal pregnancy and delivery. Cardiol Clin (2012) 1.30
Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. Cancer Res (1997) 1.25
Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc Natl Acad Sci U S A (2002) 1.24
Factors regulating trophoblast migration and invasiveness: possible derangements contributing to pre-eclampsia and fetal injury. Placenta (2003) 1.22
Evidence of a role for matrix metalloproteinases in cold preservation injury of the liver in humans and in the rat. Hepatology (1997) 1.19
Insights into MMP-TIMP interactions. Ann N Y Acad Sci (1999) 1.18
Structural basis of the adaptive molecular recognition by MMP9. J Mol Biol (2002) 1.18
Enhanced vascular reactivity during inhibition of nitric oxide synthesis in pregnant rats. Hypertension (1998) 1.16
Heparin-binding EGF-like growth factor regulates human extravillous cytotrophoblast development during conversion to the invasive phenotype. Dev Biol (2004) 1.15
Effect of angiotensin II synthesis blockade on the hypertensive response to chronic reductions in uterine perfusion pressure in pregnant rats. Hypertension (2001) 1.12
Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K+ channels: relevance to varicose vein formation. J Vasc Surg (2007) 1.11
Pre-eclampsia and expression of heparin-binding EGF-like growth factor. Lancet (2002) 1.11
Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction. J Vasc Surg (2004) 1.09
The complex between a tissue inhibitor of metalloproteinases (TIMP-2) and 72-kDa progelatinase is a metalloproteinase inhibitor. Eur J Biochem (1991) 1.08
Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells. Cancer Res (1990) 1.07
Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kgamma-dependent manner. Am J Physiol Cell Physiol (2009) 1.03
Protein kinase C in uterine and systemic arteries during ovarian cycle and pregnancy. Am J Physiol (1991) 1.03
Vascular endothelial growth factor, epidermal growth factor and fibroblast growth factor-4 and -10 stimulate trophoblast plasminogen activator system and metalloproteinase-9. Mol Hum Reprod (2004) 1.02
Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia. Cardiovasc Hematol Agents Med Chem (2010) 1.02
Expression of human recombinant 72 kDa gelatinase and tissue inhibitor of metalloproteinase-2 (TIMP-2): characterization of complex and free enzyme. Biochem J (1993) 1.01
Reduced endothelial NO-cGMP vascular relaxation pathway during TNF-alpha-induced hypertension in pregnant rats. Am J Physiol Regul Integr Comp Physiol (2002) 0.99
Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal (2009) 0.99
Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev (2012) 0.97
Chronic hypoxia increases pressure-dependent myogenic tone of the uterine artery in pregnant sheep: role of ERK/PKC pathway. Am J Physiol Heart Circ Physiol (2009) 0.97
Prolonged mechanical stretch is associated with upregulation of hypoxia-inducible factors and reduced contraction in rat inferior vena cava. J Vasc Surg (2010) 0.97
MicroRNA expression profiles in placenta with severe preeclampsia using a PNA-based microarray. Placenta (2013) 0.96
Bile acid regulates MUC2 transcription in colon cancer cells via positive EGFR/PKC/Ras/ERK/CREB, PI3K/Akt/IkappaB/NF-kappaB and p38/MSK1/CREB pathways and negative JNK/c-Jun/AP-1 pathway. Int J Oncol (2010) 0.96
Gestational hypoxia induces preeclampsia-like symptoms via heightened endothelin-1 signaling in pregnant rats. Hypertension (2013) 0.96
Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta Physiol (Oxf) (2013) 0.96
Review: The angiogenic and vasodilatory utero-placental network. Placenta (2011) 0.94
Pregnancy-associated reduction in vascular protein kinase C activity rebounds during inhibition of NO synthesis. Am J Physiol Regul Integr Comp Physiol (2000) 0.94
Maternal plasma miRNAs expression in preeclamptic pregnancies. Biomed Res Int (2013) 0.93
Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia. Biochem Pharmacol (2015) 0.92
Human gelatinase/type IV procollagenase is a regular plasma component. FEBS Lett (1989) 0.91
Increased peripheral resistance during reduced uterine perfusion pressure hypertension in pregnant rabbits. Am J Med Sci (1992) 0.91
Biological and pathobiological functions of gelatinase dimers and complexes. Connect Tissue Res (2008) 0.91
IL-6-induced pathophysiology during pre-eclampsia: potential therapeutic role for magnesium sulfate? Int J Interferon Cytokine Mediat Res (2011) 0.91
Downregulation of microvascular endothelial type B endothelin receptor is a central vascular mechanism in hypertensive pregnancy. Hypertension (2014) 0.90
Physiological remodelling of the maternal uterine circulation during pregnancy. Basic Clin Pharmacol Toxicol (2011) 0.89
Adaptation of the uterine arcade in rats to pregnancy. J Dev Physiol (1989) 0.89
Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets (2013) 0.87
MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides. J Surg Res (2008) 0.87
Control of blood flow to the gravid uterus of domestic livestock species. J Anim Sci (1995) 0.87
Changes in matrix metalloproteinases during the evolution of interstitial renal fibrosis in a rat experimental model. Pathobiology (1998) 0.87
Expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and its related extracellular matrix degrading enzymes in the endometrium during estrous cycle and early gestation in cattle. Reprod Biol Endocrinol (2010) 0.86
Evidence for declining extracellular calcium uptake and protein kinase C activity in uterine arterial smooth muscle during gestation in gilts. Biol Reprod (1992) 0.86
Reduced endothelial NO-cGMP-mediated vascular relaxation and hypertension in IL-6-infused pregnant rats. Hypertension (2004) 0.86
Matrix metalloproteinases as drug targets in preeclampsia. Curr Drug Targets (2013) 0.85
Expression of heparin-binding EGF-like growth factor in term chorionic villous explants and its role in trophoblast survival. Placenta (2008) 0.85
Reduced expression of the epidermal growth factor signaling system in preeclampsia. Placenta (2014) 0.85
Antihypertensive effects of inducible nitric oxide synthase inhibition in experimental pre-eclampsia. J Cell Mol Med (2013) 0.85
Evaluation of oxidative stress markers in first trimester for assessment of preeclampsia risk. Arch Gynecol Obstet (2011) 0.84
Increased MMPs expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones. Am J Physiol Endocrinol Metab (2012) 0.84
Altered matrix metalloproteinase-2 and -9 expression/activity links placental ischemia and anti-angiogenic sFlt-1 to uteroplacental and vascular remodeling and collagen deposition in hypertensive pregnancy. Biochem Pharmacol (2014) 0.83
Ca(2+)-insensitive vascular protein kinase C during pregnancy and NOS inhibition. Hypertension (1999) 0.82
Bovine endometrial metallopeptidases MMP14 and MMP2 and the metallopeptidase inhibitor TIMP2 participate in maternal preparation of pregnancy. Mol Cell Endocrinol (2010) 0.82
Enhanced endothelin receptor type B-mediated vasodilation and underlying [Ca²⁺]i in mesenteric microvessels of pregnant rats. Br J Pharmacol (2013) 0.82
MicroRNA-204 suppresses trophoblast-like cell invasion by targeting matrix metalloproteinase-9. Biochem Biophys Res Commun (2015) 0.81
EMMPRIN-mediated induction of uterine and vascular matrix metalloproteinases during pregnancy and in response to estrogen and progesterone. Biochem Pharmacol (2013) 0.81
Dysregulated expression of matrix metalloproteinases and their inhibitors may participate in the pathogenesis of pre-eclampsia and fetal growth restriction. Early Hum Dev (2014) 0.81